Polymorphisms Related to the Serum 25-Hydroxyvitamin D Level and Risk of Myocardial Infarction, Diabetes, Cancer and Mortality. The Tromsø Study
Open Access
- 23 May 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5), e37295
- https://doi.org/10.1371/journal.pone.0037295
Abstract
Low serum 25(OH)D levels are associated with cardiovascular risk factors, and also predict future myocardial infarction (MI), type 2 diabetes (T2DM), cancer and all-cause mortality. Recently several single nucleotide polymorphisms (SNPs) associated with serum 25-hydroxyvitamin D (25(OH)D) level have been identified. If these relations are causal one would expect a similar association between these SNPs and health. DNA was prepared from subjects who participated in the fourth survey of the Tromsø Study in 1994–1995 and who were registered with the endpoints MI, T2DM, cancer or death as well as a randomly selected control group. The endpoint registers were complete up to 2007–2010. Genotyping was performed for 17 SNPs related to the serum 25(OH)D level. A total of 9528 subjects were selected for genetic analyses which were successfully performed for at least one SNP in 9471 subjects. Among these, 2025 were registered with MI, 1092 with T2DM, 2924 with cancer and 3828 had died. The mean differences in serum 25(OH)D levels between SNP genotypes with the lowest and highest serum 25(OH)D levels varied from 0.1 to 7.8 nmol/L. A genotype score based on weighted risk alleles regarding low serum 25(OH)D levels was established. There was no consistent association between the genotype score or individuals SNPs and MI, T2DM, cancer, mortality or risk factors for disease. However, for rs6013897 genotypes (located at the 24-hydroxylase gene (CYP24A1)) there was a significant association with breast cancer (P<0.05). Our results do not support nor exclude a causal relationship between serum 25(OH)D levels and MI, T2DM, cancer or mortality, and our observation on breast cancer needs confirmation. Further genetic studies are warranted, particularly in populations with vitamin D deficiency. ClinicalTrials.gov NCT01395303Keywords
This publication has 43 references indexed in Scilit:
- Common Genetic Variants in the Vitamin D Pathway Including Genome-Wide Associated Variants Are Not Associated with Breast Cancer Risk among Chinese WomenCancer Epidemiology, Biomarkers & Prevention, 2011
- CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung AdenocarcinomaClinical Cancer Research, 2011
- Risk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of The Tromsø StudyEuropean Journal of Epidemiology, 2010
- Association of the Vitamin D Metabolism Gene CYP24A1 With Coronary Artery CalcificationArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Genome-wide association study of vitamin D concentrations in Hispanic Americans: The IRAS Family StudyThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Common genetic determinants of vitamin D insufficiency: a genome-wide association studyThe Lancet, 2010
- Genome-wide association study of circulating vitamin D levelsHuman Molecular Genetics, 2010
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization StudiesAmerican Journal of Epidemiology, 2009
- 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General PopulationArchives of Internal Medicine, 2008
- Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsNature Reviews Cancer, 2007